Vestibular schwannoma (VS) surgery has had a compelling historical evolution. This article aimed to provide a detailed narrative historical review of the chronological progression and conception of surgical VS management. Acknowledgment of the development, revision, and transformation of VS surgery over the decades facilitate a comprehensive understanding of current clinical practice and the scope for further procedural evolution. Following the commencement of VS surgery in the late 18th century, procedures and management have been perpetually revised and augmented, culminating in drastically improved surgical outcomes. This article draws upon the primary source material to provide augmented acuity into the principal pioneers and landmark cases that define the surgery's trajectory. Moreover, the article includes original interpretive artwork by the first author along with a detailed timeline to facilitate enhanced perspicacity of this unique and salient constituent in surgical history.

No abstract

Legislative change to cannabis use has generated significant interest into the therapeutic utility of cannabis-derived medical products, particularly in the field of oncology. However, much of this research has focused on adults, leaving physicians and caregivers uncertain as to the safety and efficacy of cannabinoids amongst the pediatric demographic. To this end, the aim of this review is to examine the scope of pharmaceutical cannabis in treatment of pediatric cancer, evaluating its utility as an anti-cancer therapeutic as well as symptom relief agent. This systematic review was conducted following the PRISMA guidelines. 30 included articles comprised of 16 clinical and 14 preclinical studies. There is reasonable evidence to support the use of cannabis in CINV, with plausible utility for other facets of symptomatic relief. Preclinical pediatric cancer models, investigating anti-cancer cannabinoid effect, have provided evidence that may warrant first phase clinical trials.